Abstract: Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.

Abstract: Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.

Abstract: Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.

Abstract: Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.

Abstract: Humidity and temperature may impact the physical properties of Basic Copper Nitrate (BCN), (Cu2(OH)3(NO3), BCN) inorganic particles. The use of hydrophobic surface coatings on these inorganic particles have been found to protect and/or minimize the amount of surface degradation over a period of time.

Abstract: Formulations of tegavivint and related compounds, methods of making such formulations and methods of treating various conditions utilizing such formulations.

Abstract: The present disclosure is directed to a power generating unit secured beneath a semi-trailer on an over-the-road vehicle. The power generating unit is selectively positionable from a raised position to a lowered position wherein a generating wheel is in contact with the road surface for recovering brake torque potential energy during select operational states of the vehicle. A storage battery is carried on the vehicle trailer and in electrical communication with the generator to store such excess electrical energy. Periodically, the electrical energy is made available for discharging to a stationary storage battery for sale and distribution into the power grid as supplemental energy or alternately to provide a temporary power substation.

Abstract: A system and method for conforming a decision to a compliance expression is described. In one embodiment, the method comprises receiving an intermediate conclusion generated by a decision system as a result of a policy evaluation performed based on at least one of a premise and a policy expression; performing a compliance evaluation to determine conformance of the received intermediate conclusion with a compliance expression; responsive to the performing a compliance evaluation, selectively executing a compliance statement in connection with the intermediate conclusion; and subsequent to the selectively executing, issuing a decision response, wherein the decision response conforms to the compliance expression.

Abstract: A conjugate is disclosed herein, wherein the conjugate includes a ligand having the ability to specifically and stably bind to an external receptor or binding site on a tumor vasculature endothelial cell, wherein the external receptor or binding site is specific for tumor vasculature endothelial cells. The conjugate also includes an anticancer agent that is selectively toxic to cancer cells operatively attached to the ligand. The anticancer agent may be L-methioninase. Pharmaceutical compositions comprising the conjugate are also disclosed, as well as methods of treating a cancer tumor or cancer cells with a therapeutically effective amount of the conjugate.

Abstract: The present disclosure is directed to a power generating unit secured beneath a semi-trailer on an over-the-road vehicle. The power generating unit is selectively positionable from a raised position to a lowered position wherein a generating wheel is in contact with the road surface for recovering brake torque potential energy during select operational states of the vehicle. A storage battery is carried on the vehicle trailer and in electrical communication with the generator to store such excess electrical energy. Periodically, the electrical energy is made available for discharging to a stationary storage battery for sale and distribution into the power grid as supplemental energy or alternately to provide a temporary power substation.

Abstract: Chimeric proteins comprising soluble Tissue Factor (sTF) and another subunit (e.g., annexin V) are described. The proteins promote blood clotting and/or inhibit cancer by targeting sTF to specific receptors such as phosphatidyl serine (PS) on activated cells. These chimeric proteins are useful in treating patients with excessive bleeding due to inborn problems, drug therapy, trauma or surgery and/or as an anti-cancer therapy, for example by causing blood vessels feeding cancers to become clotted, thereby preventing adequate flow of blood to a tumor, which in turn will lead to tumor inhibition and death or may be used in a therapy to cause clotting within blood vessels that pose a threat in the subject in non-cancerous conditions.

Abstract: A conjugate is disclosed herein, wherein the conjugate comprises a ligand having the ability to bind to a receptor, wherein the receptor is overexpressed on a surface of a cancer cell, and an anticancer agent selectively toxic to cancer cells coupled to the ligand. The anticancer agent may be L-methioninase. Pharmaceutical compositions comprising the conjugate are also disclosed. A method of inducing tumor cell death in vivo is also disclosed and includes contacting a population of tumor cells in vivo with a therapeutically effective amount of the conjugate.

Abstract: A formulation for use as a bactericidal agent in the human or animal digestive system includes xanthine oxidoreductase. The formulation may especially be in the form of a formula feed formulation or enteral feed formulation for administration to a human or animal. The formulation is capable of functioning as a “natural antibiotic” to prevent or reduce bacterial infection within the gut, especially the neonatal gut.

Abstract: A composition for use in the treatment of lesions of the human or animal body comprises xanthine oxidoreductase and a pharmaceutically acceptable electron donor system. The composition can accelerate wound healing, especially in a hypoxic environment.

Abstract: Automatic switching circuitry for processing input signals of more than one frequency, incorporating information for the derivation of one or more audio channels. The circuitry, including a selectively variable bandpass device, may be one of several values corresponding to the frequency of a input signal. A demultiplexing device is provided to apply a demultiplexing operation on signals output from the bandpass device, with a control logic monitoring the demultiplexing device to determine if a demultiplexing operation has been achieved, and instructing the selection of another value for the bandpass device if no demultiplexing operation was achieved for a given value of the bandpass device.